RESUMEN
To evaluate the efficacy of sufentanil combined with dexmedetomidine in patient-controlled subcutaneous analgesia (PSCA) for advanced cancer pain, 62 patients with advanced cancer pain treated in Department of Oncology of Hebei PetroChina Central Hospital from January 2017 to May 2020 were recruited and assigned via the random number table method to either the control group or the observation group. The control group (group A) received PSCA with sufentanil and the observation group was divided into group B1 receiving PSCA with sufentanil and dexmedetomidine (20:1) and group B2 given PSCA with sufentanil and dexmedetomidine (10:1). The numeric rating scale (NRS) scores of patients in the three groups decreased significantly after medication (P<0.05), with significantly lower NRS scores in groups B1 and B2 than in group A (P<0.05) and comparable results between groups B1 and B2 (P>0.05). Significantly higher Ramsay sedation scores were observed in groups B1 and B2 than in group A after drug administration (P<0.05), without significant differences between groups B1 and B2 (P>0.05). The incidence of constipation, nausea and vomiting in group B1 and group B2 was significantly lower than that in group A. PSCA with sufentanil and dexmedetomidine is effective in patients with cancer pain.
Asunto(s)
Dolor en Cáncer , Dexmedetomidina , Neoplasias , Humanos , Dolor en Cáncer/tratamiento farmacológico , Sufentanilo/efectos adversos , Dexmedetomidina/efectos adversos , Dolor/tratamiento farmacológico , Dolor/etiología , Analgesia Controlada por el Paciente , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Resultado del TratamientoRESUMEN
Diabetes is the main chronic disease that greatly affects human life. Up to now, many measures have been taken to cope with the disease, among which natural products with hypoglycemic effects have aroused great interest. The objective of this study was to evaluate the hypoglycemic effects of Morus abla L. cv. longsang 1 leaf-derived water extract in vitro and in vivo. These leaves were firstly subjected to water extraction, and the obtained products were further isolated for polysaccharides, flavonoids and alkaloids. The α-glucosidase activity and anti-protein glycosylation activity of the aqueous extracts were examined in vitro. Hyperglycemic mouse models were used to evaluate the hypoglycemic effects of the aqueous extract by blood biochemical parameters, intestinal microbiota, and pathological changes to the kidneys. The results showed that the main hypoglycemic components in the aqueous extracts were flavonoids and alkaloids and their inhibition rates against α-glucosidase activity were 86.12 ± 1.79% and 87.29 ± 1.32%, respectively. High-dose mulberry leaf water extracts can reduce the blood glucose of diabetic mice by 28.17% and improve glucose tolerance by 19.02%. Furthermore, mulberry leaf water extracts could reduce the serum free fatty acid (FFA), tumor necrosis factor-α (TNF-α), insulin and glycated serum protein content, while alleviating kidney damage and improving intestinal microbiota. These results indicated that the synergistic effects among the different components of mulberry leaves might explain their alleviating effects on diabetic syndrome and thus provide a simple, convenient way to obtain the hypoglycemic components from mulberry leaves.